Ovuloc

Quick links to important sections

Ovuloc

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ovuloc

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Oral Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Primary Purpose Pregnancy Prevention (Contraception)
Origin Synthetic Steroid Hormones
Status Prescription-only (Rx)

What Type of Medicine is Ovuloc?

Ovuloc is classified as a Combined Hormonal Contraceptive (CHC), a specialized pharmaceutical preparation designed for systemic administration via the oral route as a tablet, requiring a prescription for use. The drug belongs to the anti-ovulatory agents within the broader classification of hormonal contraceptives for systemic use. Unlike progestin-only contraceptives, Ovuloc is a combination product that delivers two active ingredients. This dual-hormone approach is clinically recognized for providing effective cycle control and pregnancy prevention for women of reproductive age. The drug is positioned as a reliable, daily-administered method of contraception.

Composition: A Combination of Synthetic Hormones

The active foundation of Ovuloc rests upon its two essential synthetic steroid hormones: Desogestrel and Ethinyl Estradiol (EE). Desogestrel functions as the progestogen component, chemically characterized as a third-generation progestin. Ethinyl Estradiol serves as the synthetic estrogen component, which is standard in CHCs. The Desogestrel and Ethinyl Estradiol combination has an established efficacy and safety profile. This specific pairing differentiates it within the CHC class and utilizes pharmaceutical-grade solid excipients to deliver the hormonal combination consistently.

Primary Purpose of Ovuloc

The general function of Ovuloc is to provide effective, reversible pregnancy prevention through systemic hormonal regulation. The combined action of the hormones works to suppress the monthly ovarian cycle, making the release of an egg (ovulation) unlikely. The formulation's design also ensures that the hormones alter the cervical mucus and modify the uterine lining, establishing a highly reliable, multi-targeted method of contraception.

Regulatory References

  1. Birth control pills - combination: MedlinePlus Medical Encyclopedia

What side effects are possible with Ovuloc?

Possible Side Effects and Safety Information

The safety profile for this medicine is characterized by a spectrum of adverse reactions ranging from common non-serious events to rare but serious vascular and hepatic risks, as documented in regulatory sources.

Adverse Reaction Classification

Classification System-Organ Class / Event Type
Common Nausea, headache, abdominal pain, irregular uterine bleeding or spotting, breast pain/tenderness, weight gain, altered mood.
Serious / Clinically Significant Venous and arterial thrombotic events (blood clots in the legs, lungs, eyes, or brain), stroke, heart attack, liver tumors, severe allergic reactions, and uncontrolled hypertension.

Serious Adverse Reactions

The most serious documented safety concerns are the increased risk of forming blood clots (thromboembolic events), including deep vein thrombosis and pulmonary embolism. There is also a noted risk for hepatic disorders, such as liver tumors and jaundice, requiring immediate discontinuation if such conditions occur.

Safety Restrictions and Limitations

Official regulatory documents establish specific restrictions on use. This medicine is contraindicated for women who are pregnant or breastfeeding. The risk of serious cardiovascular events, including blood clots, is significantly increased and often contraindicates use in women over 35 years old who smoke or who have a history of certain pre-existing conditions, such as: previous blood clots, uncontrolled high blood pressure, certain cancers, severe liver disease, or vascular complications of diabetes or migraine with aura. Temporary discontinuation is generally required before major surgery or during prolonged periods of immobility to mitigate the risk of thrombosis.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for products like Ovuloc (oral contraceptives) indicates that acute overdosage is generally not likely to be life-threatening or associated with serious long-term clinical outcomes. Management is typically supportive.

Documented Overdose Manifestations

The signs and symptoms most commonly reported following overdosage are non-serious and usually self-limiting:

  • Nausea
  • Vomiting
  • Withdrawal bleeding (may occur a few days after cessation)

Emergency Actions and Urgent Consultation

Despite the generally low risk of serious harm, immediate medical consultation is required following any suspected or confirmed overdose. Official guidance mandates the following action:

  • Seek medical help right away by calling a national Poison Control Center or other healthcare professional.

Supportive Management and Constraints

No specific pharmacological antidote exists or is recommended for oral contraceptive overdose in official labeling. Treatment focuses on symptomatic support and observation.

Regulatory documentation also notes that serious ill effects have historically not been reported following accidental ingestion by children, although symptoms such as nausea and vomiting may still occur. All cases, however, require professional medical assessment to ensure safety and provide appropriate guidance.

Therapeutic Uses of Ovuloc

What Ovuloc Treats: Main Uses and Benefits

Ovuloc (Desogestrel/Ethinyl Estradiol) is commonly used across key therapeutic domains to support patient well-being and reproductive health. Its primary therapeutic benefit is to provide reliable, reversible contraception, supporting women of reproductive age in maintaining functional stability regarding family planning.

Improving Menstrual Cycle Stability and Comfort

This medication is applied in situations involving certain distressing symptoms related to systemic imbalance, offering supportive therapeutic benefit. In addition to fertility control, it is commonly used to help with pronounced heavy menstrual bleeding (menorrhagia) and cyclical painful periods (dysmenorrhea). It may support the achievement of a more predictable cycle pattern, which generally helps maintain a sense of stability when menstrual symptoms interfere with daily functioning. The medication is applied across conditions involving episodic or fluctuating manifestations, such as symptomatic discomfort associated with endometriosis or PMDD.

Management of Hormone-Driven Skin Manifestations

Ovuloc is also considered relevant for easing symptoms that become more disruptive during flare-ups, specifically in the domain of persistent, severe Acne vulgaris. It is applied in addressing these symptoms related to heightened physiological activity, supports patients during symptomatic periods, and contributes to easing the overall symptom load.


Quick Fact: Relief for Cyclical Discomfort Ovuloc may assist in easing the symptomatic burden associated with painful and excessively heavy menstrual periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Ovuloc (Desogestrel/Ethinyl Estradiol) is permitted for use by women of reproductive age seeking pregnancy prevention. However, official regulatory bodies define strict eligibility constraints based on a patient's health status and personal factors, classifying certain populations as absolutely contraindicated (must not use).


Contraindicated Populations (Must Not Use)

Contraindication Category Examples of Non-Eligibility
Thrombotic or Vascular Risk History of blood clots (DVT/PE), stroke, myocardial infarction, or known thrombophilic conditions.
Hormone-Sensitive Conditions Current or history of breast cancer or other estrogen-dependent neoplasia.
Liver Status & Metabolism Active liver disease, hepatic tumors, or severe hypertension (uncontrolled).
Age and Lifestyle Women who smoke and are over the age of 35.

Other Eligibility Rules

Use is also prohibited during known or suspected pregnancy. The medicine is not recommended for women who are breastfeeding. It is not indicated for use in elderly women, and use in teenage females is restricted to those who have started menstruation (post-menarche). Patients must discontinue use prior to major surgery or periods of prolonged immobilization, as directed by official labeling.

What should I know about interactions with other medicines?

Ovuloc’s interaction profile is characterized by pharmacokinetic changes that affect the plasma concentration of its active hormones, desogestrel and ethinyl estradiol, and the plasma concentration of co-administered drugs.

Formally Contraindicated Combinations

Co-administration is strictly prohibited with Hepatitis C drug combinations containing ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, due to the documented risk of increased liver enzyme levels (ALT). The combination is also contraindicated in females over 35 years of age who smoke, due to an increased risk of serious cardiovascular events.

Documented Exposure-Altering Interactions

Co-administration with potent CYP3A4 enzyme inducers, such as Phenytoin, Phenobarbital, Rifampicin, Carbamazepine, and Bosentan, may decrease the plasma concentrations of the contraceptive hormones. This pharmacokinetic interaction can compromise efficacy. Conversely, the contraceptive may increase the plasma concentrations of drugs metabolized by CYP1A2, such as Tizanidine, or other co-administered agents like Cyclosporine and Glucocorticoids (e.g., Prednisolone).

Separately, the herbal supplement St. John's Wort is documented to reduce the plasma concentration of the hormones, potentially reducing the efficacy of the medicine. The official labeling also requires the medicine to be discontinued at least four weeks prior to and for two weeks after major surgery associated with an increased risk of thromboembolism.

Mechanism of Action

Central Suppression of the Ovulation Pathway

Ovuloc's mechanism is initiated by the agonism of Estrogen and Progesterone Receptors in the hypothalamus and pituitary gland. The sustained presence of these exogenous hormones induces systemic negative feedback, which suppresses the release of Gonadotropin-Releasing Hormone (GnRH), thereby drastically reducing the pituitary secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This central action prevents the natural mid-cycle LH surge, which is the required hormonal signal to trigger the release of an ovum (ovulation).


Peripheral Modification of Reproductive Tissues

In addition to the central effects, the progestin component modulates peripheral physiology by activating Progesterone Receptors in local reproductive tract tissues. This action modifies the viscosity of cervical mucus, causing it to thicken and become impermeable to sperm penetration. Concurrently, it induces structural changes in the endometrial lining, making it thin and altering its capacity for potential implantation. These peripheral effects provide an additive action to the central mechanism, contributing to the overall modulation of reproductive physiology.

Dosage and Administration Information

Ovuloc is administered solely via the oral route as a tablet. Its use follows a standardized cyclic regimen typical for combined hormonal contraceptives. The core administration involves taking one active tablet—containing 0.15 mg Desogestrel and 0.03 mg Ethinyl Estradiol—per day. This regimen is structured as mathbf21 consecutive days of active tablets, followed by a mathbf7-day interval. This interval may consist of mathbf7 inactive or placebo tablets, completing the mathbf28-day dosing cycle.

The administration protocol requires taking the tablet at approximately the same time every day to maintain a consistent serum hormone level. The tablets must be swallowed whole, with or without food, and in the sequence directed on the packaging. Initiation of the first cycle generally occurs on the first day of the menstrual period. If the start is delayed until Day 2–5, it is necessary to use an additional non-hormonal barrier method during the first mathbf7 days of tablet intake to establish protection.

The medicine is intended for continuous, long-term administration throughout the period when contraception is desired. Specific procedural instructions govern maintaining the cycle's integrity. For example, if a tablet is missed by more than mathbf12 hours, specific actions must be taken to manage the dose and maintain coverage, which often includes supplementary barrier methods for mathbf7 days. Similarly, if severe vomiting or diarrhea occurs within mathbf3 to mathbf4 hours of administration, the event is treated as a potentially missed dose due to incomplete absorption, requiring specific replacement steps. The medication is not indicated for use in postmenopausal women.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ovuloc

This overview provides a neutral summary of the scientific research that has explored the use of the combined hormonal formulation Ovuloc (Desogestrel/Ethinyl Estradiol). It focuses strictly on the types of studies conducted, the outcomes they measured, and areas where research remains limited, without offering any clinical advice or safety information.


Evidence Supporting Pregnancy Prevention (Contraception)

This research has primarily examined women of reproductive age using the medication daily, relying on pivotal clinical trials and large-scale observational cohort studies. These studies monitor the number of unintended pregnancies that occur over a defined time period, expressed as the Pearl Index.

It is important to understand that the measurements in clinical studies reflect both "perfect use" (taking the pill exactly as directed) and "typical use" (which includes non-adherence). This indicates that the effectiveness rate recorded in the studies reflects both usage patterns and potential non-adherence. Data for long-term outcomes after stopping the medication are often drawn from general class-level evidence rather than being specific to this combination.


Evidence for Studying Severe Acne

Research has explored the use of this combination in female patients whose acne symptoms were associated with periods of heightened symptom activity. These studies are typically Randomized Controlled Trials (RCTs) that compare the medication against a placebo or other similar combined hormonal pills.

The primary outcomes measured in these trials related to physical discomfort included standardized clinical measurements, such as counting the total number of lesions and scores on global assessment scales. Follow-up durations were limited in many of these dermatology-focused studies, often spanning only the first several months of use. As a result, there is limited information for long-term outcomes that characterize the durability of the outcome after the initial stabilization period, or what happens when use is discontinued.


Evidence for Examining Menstrual Symptoms

The combined hormonal therapy has been evaluated in studies that examined the treatment of conditions characterized by heavy menstrual bleeding (menorrhagia) and painful periods (dysmenorrhea). For pain, the research monitored outcomes related to patient-reported physical discomfort. For heavy bleeding, studies examined outcomes monitoring physiological strain by measuring changes in blood loss.

Evidence quality varies across studies for these secondary indications. Data specific to the desogestrel/ethinyl estradiol combination remain limited when contrasted with the broad research base for the therapeutic class.

Key Studies & References An Overview of Current Contraceptive Modalities and Historical Perspectives: A Review (Includes Pearl Index Methodology)

Frequently Asked Questions (FAQ)

Common questions about Ovuloc (FAQ)

Q: How quickly is Ovuloc supposed to start working?

A: Official guidance on when Ovuloc begins to provide coverage depends on when the first tablet is taken. If tablet intake begins on the first day of the menstrual period, the medication provides contraceptive coverage immediately, according to official guidance. If the start is delayed, regulatory advice specifies that an additional non-hormonal barrier method mathbfis mathbfrecommended for the first mathbf7 mathbfdays of tablet intake to help establish consistent coverage.

Q: How long does it usually take to see the expected effects of Ovuloc?

A: The time it takes to observe the expected effects is not associated with a definitive timeframe in the official documents. Regulatory information notes that many common and minor effects, such as nausea or breast pain, are often mathbftemporary and may resolve after the initial adjustment period as the body becomes accustomed to the medication.

Q: What happens if someone misses a dose of Ovuloc?

A: The action to take depends on the time passed. If the missed active tablet is taken less than mathbf12 mathbfhours late, the recommended action in the guidance is to take the tablet as soon as possible. Following this guidance is intended to maintain the medicine's efficacy. If the tablet is mathbf12 mathbfhours or more late, official guidance mathbfrecommends specific, comprehensive actions, which often include using a supplementary mathbfbarrier mathbfmethod for mathbf7 mathbfdays.

Q: Can Ovuloc be crushed or split if a patient has trouble swallowing pills?

A: The official administration protocol requires the tablets to be mathbfswallowed mathbfwhole. The medication mathbfshould mathbfnot be broken, chewed, or crushed prior to use. This is to help ensure the integrity of the active ingredients and consistent hormonal absorption.

Q: Does Ovuloc interact with common herbal supplements like St. John's wort?

A: Regulatory documents explicitly state that the herbal supplement mathbfSt. mathbfJohn's mathbfWort is documented to interact with the hormones in Ovuloc. This interaction is documented to reduce the mathbfplasma mathbfconcentration of the hormones, a change that may result in compromised efficacy.

Q: What kind of monitoring is typically involved when a person is on Ovuloc?

A: Official information indicates that annual physical examinations are considered good medical practice while using this type of medication. For individuals with certain existing risk factors (e.g., diabetes, high blood pressure), periodic monitoring of mathbfblood mathbfpressure, mathbfblood mathbflipids, and mathbfblood mathbfsugar mathbflevels may be necessary, according to regulatory guidance.

Q: Is Ovuloc the same type of medication as [similar common drug name]?

A: Ovuloc is classified as a mathbfCombined mathbfHormonal mathbfContraceptive (CHC), meaning it contains mathbfboth an estrogen (Ethinyl Estradiol) and a progestin (Desogestrel). This dual-hormone composition defines its type, distinguishing it from single-hormone or non-hormonal methods.

Q: What is the difference between Ovuloc and other treatments for [condition class]?

A: Ovuloc is a mathbfcombination product defined by its specific pharmaceutical ingredients: Desogestrel and Ethinyl Estradiol. This dual-hormone approach provides a mathbfmulti-mathbftargeted mechanism of action, including suppressing ovulation and altering the cervical mucus. This composition is what distinguishes it from products that use only one type of hormone.

Q: Does Ovuloc have a generic equivalent available?

A: Yes, the specific combination of active ingredients (Desogestrel/Ethinyl Estradiol) used in Ovuloc has mathbfgeneric mathbfversions approved by regulatory agencies. This means the active hormones are widely available under different brand names.

Q: Is it normal to feel [general symptom like tiredness/nausea] when starting Ovuloc?

A: Common adverse reactions, such as nausea, headache, breast tenderness, and altered mood, are listed in official documents and are mathbffrequently mathbfreported, especially during the first few months of use. Official information notes that many of these common effects are often mathbftemporary as the body adjusts.

Q: Can taking Ovuloc affect my ability to drive or operate machinery?

A: Official information does not specifically state a direct effect on driving ability. However, individuals experiencing common side effects like mathbfdizziness or mathbffatigue mathbfmay mathbfneed mathbfto mathbfavoid driving or operating machinery until they understand how the medicine affects them.

Q: Can men use Ovuloc for any reason?

A: The medicine is officially mathbfindicated and studied only for use by mathbffemales mathbfof mathbfreproductive mathbfpotential for pregnancy prevention. It is mathbfnot mathbfindicated or studied for use in men.

Q: Why is it important to take Ovuloc at the same time each day?

A: The regulatory protocol mathbfrecommends taking the tablet at approximately the mathbfsame mathbftime mathbfevery mathbfday. This consistency is mathbfrecommended to help mathbfmaintain mathbfa mathbfstable mathbfserum mathbfhormone mathbflevel, which is key to ensuring the intended contraceptive efficacy.

Q: What are the contraindications listed for Ovuloc?

A: The official labeling mathbfcontraindicates use in patients with a history of mathbfblood mathbfclots (thrombotic events), certain mathbfcancers (e.g., breast cancer), mathbfactive mathbfliver mathbfdisease, mathbfuncontrolled mathbfhigh mathbfblood mathbfpressure, and for women mathbfover mathbf35 mathbfwho mathbfsmoke. These are examples of conditions where the drug must not be used.

Q: Why do some people report seeing no change after starting Ovuloc?

A: Official studies mathbfexamine mathbfoutcomes based on both 'perfect use' (strict adherence) and 'typical use,' which mathbfincludes real-world factors like mathbfnon-mathbfadherence. Efficacy may also be reduced by certain medication interactions, severe vomiting or diarrhea, or not consistently taking the pill at the same time every day.

Q: How does Ovuloc affect blood sugar levels?

A: Regulatory documents state that combined hormonal contraceptives may interfere with mathbfblood mathbfglucose mathbfcontrol. This can reduce the effectiveness of anti-diabetic medications. This is why regulatory guidance mathbfrecommends that prediabetic and diabetic women be mathbfmonitored closely while using the medication.

Q: What is the half-life of Ovuloc?

A: The mathbfhalf-mathbflife (the time it takes for the amount of drug in the body to be reduced by half) for the mathbfactive mathbfhormones is documented in the pharmacokinetic studies that support the drug's official profile. This data provides information on how the hormones are metabolized and cleared by the body.

Q: Are there any foods that must be completely avoided when taking Ovuloc?

A: Official sources document a specific interaction with mathbfGrapefruit mathbfor mathbfgrapefruit mathbfjuice. This food mathbfmay mathbfbe mathbfbest mathbfavoided because it can increase the plasma concentration of the drug's components, according to official information.

Q: What is the difference between Ovuloc and a placebo in clinical trials?

A: In mathbfRandomized mathbfControlled mathbfTrials (RCTs) used for research, Ovuloc is the mathbfactive mathbfmedication being mathbfstudied. A mathbfplacebo, in contrast, is a tablet that looks identical to the active medicine but contains mathbfno mathbfactive mathbfdrug mathbfingredients and is used solely for research comparison.

How should Ovuloc be stored and disposed of?

How to Store and Dispose of Ovuloc?

Ovuloc (Desogestrel/Ethinyl Estradiol) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 20 C and 25 C.
Protection Keep in the original, tightly closed container and protect from excess heat, moisture, and light. Do not store in the bathroom.
Safety It is mandatory to keep the medication out of the sight and reach of children (e.g., in a secure, up-and-away location).
Stability Do not use the tablets after the printed expiry date.

Disposal Rules

Expired or unneeded Ovuloc should not be flushed down the toilet or poured down a drain, as this violates environmental protection guidelines. To dispose of the product, official instructions require removing the tablets from the packaging, mixing them with an undesirable substance (such as dirt or coffee grounds), sealing the mixture in a bag or container, and placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ovuloc found in:

A-Z Index: